Nykode Therapeutics As (VACBF) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the NICO Therapeutics Second Quarter 2025 Strategy Update and Results Webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. You may ask a question at any time by typing it into the Ask a Question feature on your screen. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to CEO Michael Ensig. Please go ahead, Michael. Thank you very much, Kevin, and also from my side, a very warm welcome to everybody to this Q2 webcast, and not least, our long-anticipated strategy update from MyCode. Before moving on, I just want to remind every one of you of our forward-looking statements. We assume you are familiar with those, and on that basis, I'll quickly move on. As usual, I am very pleased to have with me here today Ander Fredriksson, our co-founder and CSO, and Al Gurvin, our CFO. Before moving into the strategy update, which I believe you've all been waiting for at this time point here, we'll just very quickly or briefly review the key highlights from our Q2 report, which was also announced or issued this morning here. And because we are focusing most of this call today on the strategy, we'll be reviewing the Q2 a little bit briefer than usual. Still, we did have a couple of very important events during the quarter from the VPT NEO program. We did announce key data from our NO2 trial at ASCO in 2025 in Chicago. And these data, once again, highlight our VP10neo program's ability to induce a robust and durable immune responses across multiple tumor types in a heavily pretreated patient population. And just to remind you here that the number of biotech companies that do have an established manufacturing platform, an epitope selection a...